Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...

The French drugmaker on Monday announced progress on a deal to sell 50% of its over-the-counter division to Clayton Dubilier ...

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...

MC: There is no old or new model, but there is old school thinking and open school thinking. We are clearly conscious of this within Sanofi and we truly believe that we will overcome the future ...

Sanofi said this morning that its pipeline includes ... build-up to an R&D presentation to investors that will be held in New York later today, and also after the France-headquartered group ...

French healthcare company Sanofi has decided to halt work on its once praised breast cancer medication amcenestrant after a second failed clinical trial. A possible new coronavirus vaccine ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi is deepening its commitment to targeted radiation treatments for cancer with a €300 million equity investment in a new entity pursuing next-generation radioligand therapies. The new ...

French pharmaceutical company Sanofi had asked suitors to revise their proposals for the Opella business, Bloomberg News reported earlier this week. The new bids may exclude parts of the Gold Bond ...

This newsletter was penned in the company of some mastodon fossils in New York. They say good morning, too. Today, we see an escalating battle between Eli Lilly and compounding pharmacies putting ...